COMMUNIQUÉS West-GlobeNewswire

-
Transactions under Novozymes’ stock buyback program
27/05/2019 -
Additional agenda item for Annual General Meeting of shareholders of Joint Stock Company Olainfarm to be held on June 17th, 2019
27/05/2019 -
JSC Olainfarm invites to Investor Conference - Webinar to present 1st Quarter 2019 results and the company’s new management
27/05/2019 -
Zealand Pharma to attend Jefferies and Goldman Sachs Global Healthcare Conferences
27/05/2019 -
Ossur Hf : Major shareholder announcement
27/05/2019 -
Ventura Cannabis (VCAN) Updates Investor Presentation After Reaching Several Milestones; Adds Senior Managers to Support Growth Plan; Announces Investor Meetings in Toronto
27/05/2019 -
Emerald Completes Issuance of Shares in Lieu of Cash Due for Verdélite Acquisition
27/05/2019 -
Ossur Hf : Major shareholder announcement
27/05/2019 -
Share buy-back week 21/2019
27/05/2019 -
Auxly Reports Q1 2019 Financial Results and Highlights Key Milestones
27/05/2019 -
Sequana Medical Announces Presentation of Positive DSR Clinical Proof-of-Concept Data Demonstrating Potential in Volume Overload Due to Heart Failure
27/05/2019 -
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
27/05/2019 -
BOAZ Pharmaceuticals Inc. Celebrates Sales Licence Granted In Record Time
25/05/2019 -
Aptose Biosciences Establishes New At-The-Market Facility
24/05/2019 -
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019 -
DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors
24/05/2019 -
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2019, ainsi que la nomination de Madame Viviane Monges en tant que membre du conseil d’administration
24/05/2019 -
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24/05/2019 -
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019
Pages